William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai discusses the outcomes of the TITAN study in metastatic castration-sensitive prostate cancer (mCSPC).
Advertisement
By Editor
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai discusses the outcomes of the TITAN study in metastatic castration-sensitive prostate cancer (mCSPC).